Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

Grade Last Price % Change Price Change
F 13.75 -0.51% -0.07
KPTI closed down 0.51 percent on Monday, March 1, 2021, on 64 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical KPTI trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -0.51%
Expansion Breakdown Bearish Swing Setup -0.51%
Lower Bollinger Band Touch Weakness -0.51%
Oversold Stochastic Weakness -0.51%
Outside Day Range Expansion -5.56%
Oversold Stochastic Weakness -5.56%
Older End-of-Day Signals for KPTI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 6 hours ago
Fell Below Previous Day's Low about 6 hours ago
New 52 Week Low about 6 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Lower Bollinger Band Support about 11 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Karyopharm Therapeutics Inc. Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Lymphoma Chemotherapy Occupational Safety And Health Dogs Stage Pharmaceutical Antibody Drug Conjugates Pixantrone

Is KPTI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.04
52 Week Low 13.605
Average Volume 2,958,215
200-Day Moving Average 16.22
50-Day Moving Average 15.52
20-Day Moving Average 15.08
10-Day Moving Average 14.64
Average True Range 0.78
ADX 15.06
+DI 18.20
-DI 23.14
Chandelier Exit (Long, 3 ATRs ) 15.06
Chandelier Exit (Short, 3 ATRs ) 15.93
Upper Bollinger Band 16.58
Lower Bollinger Band 13.58
Percent B (%b) 0.06
BandWidth 19.90
MACD Line -0.38
MACD Signal Line -0.23
MACD Histogram -0.149
Fundamentals Value
Market Cap 1.01 Billion
Num Shares 73.6 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -3.87
Price-to-Sales 12.93
Price-to-Book 14.87
PEG Ratio -0.15
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.54
Resistance 3 (R3) 14.58 14.35 14.41
Resistance 2 (R2) 14.35 14.15 14.33 14.36
Resistance 1 (R1) 14.05 14.03 13.94 14.01 14.32
Pivot Point 13.83 13.83 13.77 13.81 13.83
Support 1 (S1) 13.53 13.63 13.42 13.49 13.18
Support 2 (S2) 13.30 13.50 13.28 13.14
Support 3 (S3) 13.00 13.30 13.09
Support 4 (S4) 12.96